BioCryst to Present at Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
BioCryst Pharma (BCRX) PT Raised to $18 at Cowen
May 6, 2021 10:19 AM EDTCowen analyst Ken Cacciatore raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $18.00 (from $16.00) while maintaining an Outperform rating.
The analyst commented, "BioCryst reported strong first full quarter Orladeyo sales, and we view the initial launch metrics of meaningful patient switches (vs. clinical trial... More
